Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

June 20, 2024

https://www.globenewswire.com/news-release/2024/06/20/2901762/0/en/Altamira-Therapeutics-Highlights-Newly-Published-Review-Article-Supporting-Use-of-Betahistine-in-Vertigo-Management.html

Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) —

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today highlighted the publication of an article describing the rationale for and use of betahistine in the treatment of residual dizziness following standard of care physical repositioning procedures for benign paroxysmal positional vertigo (BPPV). The peer reviewed article was published by an international group of medical and scientific experts in vestibular disorders in the journal Frontiers in Neurology1 and reviews the potential causes of residual dizziness, which has been reported to occur in 31-61% of patients, and available treatment options.  

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.